What is Synlogic?
Synlogic is pioneering the application of synthetic biology to create transformative medicines. The company utilizes a proprietary, modular platform for microbial engineering to design Synthetic Biotic medicines. These innovative therapies are engineered to target validated underlying biology, offering new treatment modalities for various diseases. Synlogic's pipeline includes Synthetic Biotics aimed at metabolic disorders such as phenylketonuria (PKU), enteric hyperoxaluria, and homocystinuria, alongside a growing portfolio of partner-able assets in immunology. The company's approach represents a significant advancement in drug development, leveraging biological engineering to address unmet medical needs.
How much funding has Synlogic raised?
Synlogic has raised a total of $283.9M across 6 funding rounds:
Series A
$34.4M
Series B
$40M
Series C
$42M
Stock Offering
$57.5M
Stock Offering
$30M
Corporate Investment
$80M
Series A (2014): $34.4M with participation from Bill & Melinda Gates Foundation, NEA, and Atlas Ventures
Series B (2016): $40M led by Atlas Ventures, OrbiMed, Deerfield Management Company, and NEA
Series C (2017): $42M supported by OrbiMed, Aju IB Investment, CLI Ventures, Perceptive Advisors, NEA, Deerfield, Ally Bridge Group, Arctic Aurora LifeScience, Rock Springs Capital, and Atlas Ventures
Stock Issuance/Offering (2018): $57.5M featuring Undisclosed
Stock Issuance/Offering (2018): $30M backed by Undisclosed
Corporate Investment (2019): $80M with participation from Ginkgo Bioworks
Key Investors in Synlogic
Ginkgo Bioworks
Ginkgo Bioworks is a biotechnology company developing a horizontal platform for cell programming, used to program cells on behalf of their customers. The company was founded in 2009 and is headquartered in Boston, Massachusetts.
Bill & Melinda Gates Foundation
Established in 2000 and headquartered in Seattle, Washington, The Bill & Melinda Gates Foundation is an organization that focuses on supporting individuals experiencing hunger and extreme poverty in leading healthier lives.
Atlas Ventures
Atlas Venture is a pioneering early-stage venture capital firm focused on creating and building breakthrough biotechnology companies that translate cutting-edge science into life-changing medicines. The firm partners with exceptional life science entrepreneurs to support the launch and growth of innovative biotech startups.
What's next for Synlogic?
The substantial enterprise-level funding and strategic investment Synlogic has garnered indicate a strong market confidence in its synthetic biology platform and therapeutic pipeline. This capital infusion is expected to accelerate the development and clinical progression of its Synthetic Biotic medicines, particularly for metabolic and immunological conditions. The company is well-positioned to advance its proprietary pipeline and explore new therapeutic avenues, potentially solidifying its role as a leader in the synthetic biology therapeutics space. Future growth will likely involve further pipeline expansion, strategic partnerships, and advancing its lead candidates through clinical trials.
See full Synlogic company page
